Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 9, 2018, Pages 2158-2162

  Halstead, Scott B ^a  

^a private consultancy   (United States)

Author keywords

antibody dependent enhancement; dengue; serious adverse event; severe dengue; vaccine

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

CAUSE OF DEATH; CHILD; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG SAFETY; FOLLOW UP; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; NOTE; PHASE 3 CLINICAL TRIAL; RISK FACTOR; SEROPREVALENCE; VACCINATION; YELLOW FEVER; FEMALE; MALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT FAILURE;

CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DENGUE; DENGUE VACCINES; FEMALE; HOSPITALIZATION; HUMANS; MALE; TREATMENT FAILURE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; YELLOW FEVER;

EID: 85046028109     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2018.1445448     Document Type: Note

References (31)

1. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015;373:1195–206. doi:10.1056/NEJMoa1506223. PMID:26214039
2. WHO. Addendum to report of the Global Advisory Committee on Vaccine Safety, 10–11 June 2015. Safety of CYD-TDV dengue vaccine. Weekly Epidemiological Record. 2015;90:421–32
3. WHO. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. In: Department of Immunization VaB, ed. Geneva, Switzerland: World Health Organization; 2008:441
4. WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016, conclusions and recommendations. Weekly Epidemiological Record. 2016;91:265–84. PMID:27236868
5. WHO. Dengue vaccine: WHO position paper, July 2016–recommendations. Vaccine. 2017;35:1200–1. doi:10.1016/j.vaccine.2016.10.070. PMID:28185744
6. WHO. Updated Questions and Answers related to the dengue vaccine Dengvaxia® and its use. Published 22 December 2017. In: Immunization VaB, ed. Geneva: WHO; 2017. Available from: http://www.who.int/immunization/diseases/dengue/q_and_a_dengue_vaccine_dengvaxia_use/en/
7. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643–7. doi:10.1016/j.vaccine.2016.02.004. PMID:26873054
8. Halstead SB. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg. 2016;95:741–5. doi:10.4269/ajtmh.16-0222. PMID:27352870
9. Russell PK, Halstead SB. Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines. PLoS Negl Trop Dis. 2016;10:e0004854. doi:10.1371/journal.pntd.0004854. PMID:27513928
10. Ferguson N, Rodriguez-Barraquer I, Dorigatti I, Mier-y-Teran-Romero L, Laydon DJ, Cummings DAT. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science. 2016;353:1033–36. doi:10.1126/science.aaf9590. PMID:27701113
11. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–67. doi:10.1016/S0140-6736(12)61428-7. PMID:22975340
12. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–65. doi:10.1016/S0140-6736(14)61060-6. PMID:25018116
13. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. 2014;372:113–23. doi:10.1056/NEJMoa1411037. PMID:25365753
14. Coudeville L, Baurin N, Vergu E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine. 2016;34:6417–25. doi:10.1016/j.vaccine.2015.11.023. PMID:26614588
15. Secretariat. Background Paper on Dengue Vaccines, SAGE Working Group on Dengue Vaccine. Geneva: World Health Organization; 2016
16. Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses Adv Virus Research. 2003;60:421–67. doi:10.1016/S0065-3527(03)60011-4
17. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Soegijanto S, Nimmannitya S, Soegijanto S, Vaughn DW, Endy TP, et al. Infant dengue hemorrhagic fever: Research opportunities ignored. Emerg Infect Dis. 2002;12:1474–9. doi:10.3201/eid0812.020170
18. WHO. Global Advisory Committee on Vaccine Safety, 6–7 December 2017. Weekly Epidemiological Record. 2018;3:18–30
19. Martinez-Vega RA, Carrasquila G, Luna E, Ramos-Castaneda J. ADE and dengue vaccination. Vaccine. 2017;35:3910–2. doi:10.1016/j.vaccine.2017.06.004. PMID:28623027
20. Harenberg A, de Montfort A, Jantet-Blaudez F, Bonaparte M, Boudet F, Saville M, Jackson N, Guy B. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. PLoS Negl Trop Dis. 2016;10:e0004830. doi:10.1371/journal.pntd.0004830. PMID:27459266
21. Olivera-Botello G, Coudeville L, Fanouillere K, Guy B, Chambonneau L, Noriega F, Jackson N, CYD-TDV Vaccine Trial Group. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America. J Infect Dis. 2016;214:994–1000. doi:10.1093/infdis/jiw297. PMID:27418050
22. Gessner BD, Halsey N. Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence? Vaccine. 2017;35:3452–6. doi:10.1016/j.vaccine.2017.05.003. PMID:28528764
23. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14:45–54. doi:10.1038/nrmicro.2015.2. PMID:26639777
24. WHO. Dengue vaccine: WHO position paper–July 2016. Weekly Epidemiological Record. 2016;91:349–64. PMID:27476189
25. Flasche S, Jit M, Rodriguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, et al. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Med. 2016;13:e1002181. doi:10.1371/journal.pmed.1002181. PMID:27898668
26. Global Vaccine Safety Blueprint. WHO/IVB/12.07. WHO, Geneva, 2012. pp 38
27. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva: WHO Technical Report Series, 2011. Annex 2 2011
28. Edelman R, Hombach J. “Guidelines for the clinical evaluation of dengue vaccines in endemic areas”: Summary of a World Health Organization Technical Consultation. Vaccine. 2008;26:4113–9. doi:10.1016/j.vaccine.2008.05.058. PMID:18597906
29. Halstead SB. Critique of World Health Organization Recommendation of a Dengue Vaccine. J Infect Dis. 2016;214:1793–5. doi:10.1093/infdis/jiw340. PMID:27496975
30. Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T. Population perspectives and WHO recommendations for CYD-TDV dengue vaccine. J Infect Dis. 2016. doi:10.1093/infdis/jiw341. PMID:26747708
31. Halstead SB. Dengue Vaccine Efficacy: Not a Zero Sum Game. J Infect Dis. 2016;214:2014. doi:10.1093/infdis/jiw458. PMID:27694632